Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
Trastuzumab, a humanized monoclonal antibody derived from recombinant DNA, is used in patients with breast cancer with HER2 gene amplification. The survival benefit from trastuzumab has been well established in patients with early and metastatic breast cancer who had over expression of HER2. We repo...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2020-07-01
|
| Series: | Open Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/med-2020-0201 |
| _version_ | 1818695781293490176 |
|---|---|
| author | Zhou Qiong Dong Jie Jiang Xiaodong Pan Yueyin Han Xinghua |
| author_facet | Zhou Qiong Dong Jie Jiang Xiaodong Pan Yueyin Han Xinghua |
| author_sort | Zhou Qiong |
| collection | DOAJ |
| description | Trastuzumab, a humanized monoclonal antibody derived from recombinant DNA, is used in patients with breast cancer with HER2 gene amplification. The survival benefit from trastuzumab has been well established in patients with early and metastatic breast cancer who had over expression of HER2. We reported a case of severe thrombocytopenia after eight cycles of trastuzumab treatment for breast cancer. Before the 9th trastuzumab treatment, the patient’s platelet decreased to 48 × 109/L. Recombinant human thrombopoietin was used, and the platelet level increased to normal level. Before the 10th treatment, the platelet count of the patient was 99 × 109/L. However, during the 10th and 11th trastuzumab treatment, the platelet count decreased to 5 × 109/L in 24 h. After treatment with TPO and corticosteroids, the platelet levels increased to the normal level in 7 days. Trastuzumab-induced thrombocytopenia is rare but still occurred even after 8 cycles of trastuzumab treatment. |
| first_indexed | 2024-12-17T13:50:55Z |
| format | Article |
| id | doaj.art-ad4a2db66ed04c19b9f7f4dd7d53d0a6 |
| institution | Directory Open Access Journal |
| issn | 2391-5463 |
| language | English |
| last_indexed | 2024-12-17T13:50:55Z |
| publishDate | 2020-07-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Open Medicine |
| spelling | doaj.art-ad4a2db66ed04c19b9f7f4dd7d53d0a62022-12-21T21:46:03ZengDe GruyterOpen Medicine2391-54632020-07-0115165966210.1515/med-2020-0201med-2020-0201Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatmentZhou Qiong0Dong Jie1Jiang Xiaodong2Pan Yueyin3Han Xinghua4Department of Oncology, Provincial Hospital affiliated to Anhui Medical University, Hefei, Anhui Province, 230032, ChinaDepartment of Oncology, Provincial Hospital affiliated to Anhui Medical University, Hefei, Anhui Province, 230032, ChinaThe First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province, 230001, ChinaThe First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province, 230001, ChinaDepartment of Oncology, Provincial Hospital affiliated to Anhui Medical University, Hefei, Anhui Province, 230032, ChinaTrastuzumab, a humanized monoclonal antibody derived from recombinant DNA, is used in patients with breast cancer with HER2 gene amplification. The survival benefit from trastuzumab has been well established in patients with early and metastatic breast cancer who had over expression of HER2. We reported a case of severe thrombocytopenia after eight cycles of trastuzumab treatment for breast cancer. Before the 9th trastuzumab treatment, the patient’s platelet decreased to 48 × 109/L. Recombinant human thrombopoietin was used, and the platelet level increased to normal level. Before the 10th treatment, the platelet count of the patient was 99 × 109/L. However, during the 10th and 11th trastuzumab treatment, the platelet count decreased to 5 × 109/L in 24 h. After treatment with TPO and corticosteroids, the platelet levels increased to the normal level in 7 days. Trastuzumab-induced thrombocytopenia is rare but still occurred even after 8 cycles of trastuzumab treatment.https://doi.org/10.1515/med-2020-0201trastuzumabthrombocytopeniabreast cancer |
| spellingShingle | Zhou Qiong Dong Jie Jiang Xiaodong Pan Yueyin Han Xinghua Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment Open Medicine trastuzumab thrombocytopenia breast cancer |
| title | Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment |
| title_full | Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment |
| title_fullStr | Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment |
| title_full_unstemmed | Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment |
| title_short | Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment |
| title_sort | trastuzumab induced thrombocytopenia after eight cycles of trastuzumab treatment |
| topic | trastuzumab thrombocytopenia breast cancer |
| url | https://doi.org/10.1515/med-2020-0201 |
| work_keys_str_mv | AT zhouqiong trastuzumabinducedthrombocytopeniaaftereightcyclesoftrastuzumabtreatment AT dongjie trastuzumabinducedthrombocytopeniaaftereightcyclesoftrastuzumabtreatment AT jiangxiaodong trastuzumabinducedthrombocytopeniaaftereightcyclesoftrastuzumabtreatment AT panyueyin trastuzumabinducedthrombocytopeniaaftereightcyclesoftrastuzumabtreatment AT hanxinghua trastuzumabinducedthrombocytopeniaaftereightcyclesoftrastuzumabtreatment |